BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)
Authors:
Open Access
- 23 October 2018
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii201-viii202